Malta vs New Zealand: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Malta
0.0%
in 2024
New Zealand
0.0%
in 2024
Malta rank
167th
New Zealand rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Malta
- New Zealand
How they compare
Malta currently reports 0.0% against 0.0% in New Zealand, a difference of 0.0%.
Across all 10 years both countries report, New Zealand has been ahead every year.
Malta ranks 167th and New Zealand ranks 167th of 246 countries.
New Zealand has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Malta | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 0.1% | 0.1% | New Zealand |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Malta or New Zealand?
- Malta, at 0.0% against 0.0% in New Zealand as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Malta and New Zealand?
- 0.0%, with Malta ahead.
- How many years of comparable data are there for Malta and New Zealand?
- 10 years are reported by both, from 2015 to 2024.
- How do Malta and New Zealand rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Malta ranks 167th and New Zealand ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.